Unicycive Therapeutics, Inc. (UNCY) stock
UNCYNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.57−0.13 (-3.51%)
Close on Nov 18, 2026Market cap $99.44MP/E –Yield –
Unicycive Therapeutics cash
Cash and short-term investments held at the end of each period.
Unicycive Therapeutics's cash was $61.43M at Jun 30, 2026. For fiscal 2025 it was $41.27M, up 57.9% from the year before. The highest annual figure on record is $41.27M in fiscal 2025.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $41.27M | +57.9% |
| FY2024 | Dec 31, 2024 | $26.14M | +169.5% |
| FY2023 | Dec 31, 2023 | $9.70M | +2032.1% |
| FY2022 | Dec 31, 2022 | $455.00K | -97.3% |
| FY2021 | Dec 31, 2021 | $16.58M | +110426.7% |
| FY2019 | Dec 31, 2019 | $15.00K | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $61.43M | +175.1% |
| Q1 FY2026 | Mar 31, 2026 | $54.59M | +176.1% |
| Q4 FY2025 | Dec 31, 2025 | $41.27M | +57.9% |
| Q3 FY2025 | Sep 30, 2025 | $42.70M | +32.0% |
| Q2 FY2025 | Jun 30, 2025 | $22.33M | -46.6% |
| Q1 FY2025 | Mar 31, 2025 | $19.77M | -59.6% |
| Q4 FY2024 | Dec 31, 2024 | $26.14M | +169.5% |
| Q3 FY2024 | Sep 30, 2024 | $32.35M | +125.5% |
| Q2 FY2024 | Jun 30, 2024 | $41.78M | +122.0% |
| Q1 FY2024 | Mar 31, 2024 | $48.93M | +101.1% |
| Q4 FY2023 | Dec 31, 2023 | $9.70M | +2032.1% |
| Q3 FY2023 | Sep 30, 2023 | $14.35M | +104.6% |
| Q2 FY2023 | Jun 30, 2023 | $18.82M | +78.0% |
| Q1 FY2023 | Mar 31, 2023 | $24.33M | +78.6% |
| Q4 FY2022 | Dec 31, 2022 | $455.00K | -97.3% |
| Q3 FY2022 | Sep 30, 2022 | $7.01M | -61.1% |
| Q2 FY2022 | Jun 30, 2022 | $10.57M | +1057200.0% |
| Q1 FY2022 | Mar 31, 2022 | $13.62M | +9165.3% |
| Q4 FY2021 | Dec 31, 2021 | $16.58M | +26215.9% |
| Q3 FY2021 | Sep 30, 2021 | $18.01M | +1801000.0% |
| Q2 FY2021 | Jun 30, 2021 | $1.00K | -93.3% |
| Q1 FY2021 | Mar 31, 2021 | $147.00K | – |
| Q3 FY2020 | Sep 30, 2020 | $63.00K | – |
| Q2 FY2020 | Jun 30, 2020 | $1.00K | – |
| Q4 FY2019 | Dec 31, 2019 | $15.00K | – |
See a number that looks wrong?